Twist Bioscience, Broad Institute partner

By The Science Advisory Board staff writers

October 13, 2021 -- Twist Bioscience and the Broad Institute have created a custom next-generation sequencing (NGS) target enrichment exome panel to be used to research cancer and rare and inherited disease genes.

Twist will market the exome panel as the Twist Alliance Clinical Research Exome. The offering will help support the Broad Institute's genomics platform and was designed using validated data from clinical patient samples, Twist said.

The panel leverages Twist's NGS platform to customize content, resulting in a comprehensive survey of the exome with supplemental enrichment of clinically relevant areas of the genome related to cancer and rare and inherited diseases. By leveraging the uniformity of Twist NGS probes, the assay enables a per sample cost and throughput efficiency that Broad has already leveraged to process more than 250,000 samples to date.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.